Follow by Email

Tuesday, February 1, 2011

CSL Grant

In the fall I applied for an advocacy grant from CSL Behring on behalf of the Midwest Hemophilia Chapter. I am attaching the grant below!

Grant provides support for patient initiative to obtain passage of Standards of Care.

King of Prussia, Pennsylvania, January 20, 2011 – CSL Behring, a global leader in the plasma protein biotherapies industry and a subsidiary of CSL Limited (ASX:CSL), has awarded an advocacy grant to the Midwest Hemophilia Association (MHA) through the Local Empowerment for Advocacy Development (LEAD) program. LEAD grants support the grassroots advocacy efforts of organizations committed to helping people who use plasma-derived or recombinant therapies to manage rare and serious diseases.

MHA will use its LEAD grant to bolster legislative efforts in support of passage of Standards of Care for People with Bleeding Disorders in Missouri. In addition, MHA will start grassroots advocacy in Kansas and also help educate the public about women’s bleeding disorders.
“MHA is delighted to receive this generous LEAD grant from CSL Behring. This grant will help our ultimate goal to make all our members better self-advocates,” Kristin Marema, MHA Board Member, said.
LEAD grants total $500,000 since 2008
According to Dennis Jackman, CSL Behring’s Senior Vice President, Public Affairs, the company has awarded 33 grants totaling approximately $500,000 since the LEAD program was established in 2008. Almost $100,000 was awarded in the current grant cycle to six patient organizations including MHA.
“CSL Behring is pleased to recognize and support these organizations, all of which play a vital role in expanding patient access to information and healthcare,” said Dennis Jackman, Senior Vice President, Public Affairs, CSL Behring. “We hope that these grants will help improve the lives of people with bleeding disorders, immune deficiencies and hereditary angioedema.”

No comments: